To The Moon

$Oscar Health, Inc.(OSCR)$

Oscar Health (NYSE: OSCR), once one of the most anticipated disruptors in the U.S. health insurance market, has seen its stock price tumble sharply in recent months. The company, which went public in 2021 amid high hopes that its tech-driven approach would revolutionize the industry, now faces mounting skepticism from Wall Street and investors alike.

Is this just another rough patch for a young company still finding its footing in a complex, highly regulated sector? Or are the recent declines in Oscar’s stock a sign of deeper, perhaps existential challenges? In this article, we examine the factors behind the stock’s plunge, analyze the company’s current fundamentals, assess the competitive and regulatory landscape, and explore whether there is a path forward—or if the end may indeed be near.

From Promising Disruptor to Investor Disappointment

When Oscar Health debuted on the New York Stock Exchange in March 2021, it carried with it the ambitions of being “the insurance company that really cares.” Leveraging a user-friendly app, AI-driven care recommendations, and a direct-to-consumer marketing approach, Oscar positioned itself as the next-generation insurer for millennials and Gen Z customers disenchanted with legacy health plans.

The IPO was met with enthusiasm, valuing the company at nearly $8 billion. Investors latched onto the narrative of Oscar as a tech-enabled challenger in an industry infamous for its complexity, opacity, and customer dissatisfaction.

But within months, cracks began to appear. The stock fell more than 70% in its first year as earnings reports revealed steep losses, ballooning medical loss ratios, and an inability to achieve scale sufficient to offset high customer acquisition costs.

Why the Stock Has Been Falling

Oscar’s share price has continued to decline through 2024, with the latest drop attributed to a combination of factors:

Widening Losses and Margin Pressures

Despite steady growth in membership—now topping 1.2 million—Oscar has yet to turn a profit. In its most recent quarterly earnings, the company reported a net loss of $128 million, wider than analysts expected. The all-important Medical Loss Ratio (MLR)—the percentage of premium revenues spent on claims—remained stubbornly above 90%, well above the long-term target of mid-80s.

The company’s administrative expenses remain high, a byproduct of heavy investment in technology and customer acquisition, and its path to profitability has been pushed further out, raising doubts about its financial sustainability.

Competitive and Regulatory Challenges

Oscar operates in an industry dominated by entrenched giants such as UnitedHealth Group, Anthem (Elevance), and CVS Health’s Aetna. These incumbents enjoy scale, deep provider networks, and regulatory expertise that make it difficult for upstarts like Oscar to compete effectively.

In addition, Oscar’s bet on the Affordable Care Act (ACA) exchanges means it is vulnerable to political and regulatory shifts. Recent uncertainty over subsidy extensions and Medicaid unwinding has introduced more volatility into its target market.

Market Sentiment and Rising Rates

Broader market factors have also weighed on Oscar’s stock. Rising interest rates have made unprofitable growth stocks less attractive to investors, who are now favoring companies with predictable cash flows and proven profitability. As part of a cohort of post-pandemic IPOs that have underperformed, Oscar has become a cautionary tale for speculative growth investing.

Current Fundamentals: A Closer Look

While the headlines have been brutal, Oscar’s operating metrics offer a more nuanced picture.

The company continues to grow its membership base, which is crucial in an industry where scale directly drives profitability. Its technology platform has shown promise in improving member engagement, reducing emergency room visits, and promoting preventive care—all positive for long-term cost control.

Oscar has also begun to pivot toward higher-margin, less capital-intensive segments, such as providing its technology platform to other insurers and health plans. Its partnership with Cigna to offer co-branded plans demonstrates its willingness to adapt and find creative ways to grow.

However, the path to breakeven remains steep. Consensus estimates suggest the company may not turn a profit before 2027, even under optimistic scenarios. Cash burn, while lower than in earlier years, remains a concern, with about $1.1 billion in liquidity on hand as of the last report.

Is Oscar’s Business Model Fundamentally Flawed?

At the heart of the debate over Oscar’s future is a simple question: does its model actually work?

Supporters argue that the U.S. health insurance market is ripe for disruption. Consumers demand more transparency, digital-first experiences, and personalized care—all areas where Oscar excels. If it can continue growing its customer base while driving down costs through technology, it could carve out a sustainable niche.

Critics, however, point to structural issues. Health insurance is a low-margin, scale-driven business with high fixed costs and razor-thin operating leeway. The very features that make Oscar appealing to consumers—such as high-touch support and intuitive tech—are costly to provide. Moreover, its customer base skews younger and less profitable, limiting revenue potential.

Unless Oscar can drastically improve its operating leverage, skeptics warn it may never generate consistent profits, regardless of market size or demand trends.

Lessons From Other Disruptors

Oscar is not the first company to try to shake up a calcified industry. Companies like Lemonade in insurance and Teladoc in telehealth have experienced similar trajectories: fast early growth, soaring valuations, and then sharp corrections as investors recalibrated expectations.

Some of these companies have managed to find their footing by pivoting, cutting costs, or narrowing their focus. Others have languished, unable to overcome fundamental economic realities.

Oscar’s future likely depends on whether it can emulate the former rather than the latter—cutting its loss ratio, scaling up profitably, and finding sustainable revenue streams beyond ACA exchanges.

What the Future Holds

For investors, Oscar’s current share price—down more than 85% from its IPO peak—reflects a deeply discounted view of its prospects. That presents both risk and opportunity.

On the bullish side, a few key developments could catalyze a turnaround:

• A decline in MLR as technology-driven cost savings kick in.

• Continued membership growth and scale economies.

• Successful monetization of its technology platform through partnerships.

• A more favorable regulatory environment.

On the bearish side, however, risks abound:

• Further cash burn and potential need for dilutive capital raises.

• Entrenched competitors eroding market share.

• Political changes affecting ACA exchange economics.

Investors will need to watch closely for signs of execution and discipline over the next 12–24 months.

Conclusion: Is This the End?

The plummet in Oscar Health’s stock price has understandably rattled investors. Yet while the company’s challenges are substantial, it is premature to declare the end.

Oscar still commands a differentiated brand, innovative technology, and a growing customer base in a massive, under-innovated market. But its path forward will require a combination of cost discipline, strategic focus, and perhaps a bit of luck in the regulatory and macroeconomic backdrop.

For long-term, risk-tolerant investors, Oscar may still have a place as a speculative position—provided they can stomach further volatility. For others, it may be prudent to wait for clearer signs of stabilization before re-entering the stock.

One thing is certain: Oscar Health’s story is far from over. Whether it ends as a cautionary tale or an unlikely comeback story remains to be seen.

Disclaimer: I want to make it clear that I am not a financial advisor, and nothing I say is intended to be a recommendation to buy or sell any financial instrument. Additionally, it's important to remember that there are no guarantees or certainties in trading or investing, and you should never invest money that you can't afford to lose.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub